Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aknichthol is a topical anti-acne medication developed by Ichthyol-Gesellschaft Cordes Hermanni & Co, specifically formulated for the treatment of various forms of acne, including acne vulgaris. It is a combination product containing light sodium bituminosulfonate (Ichthyol-Sodium, light) and salicylic acid. Sodium bituminosulfonate is a sulfonated shale oil derivative that exhibits anti-inflammatory, antimicrobial, and anti-seborrheic properties, which help to reduce the redness, bacterial load (particularly *Cutibacterium acnes*), and oiliness associated with acne lesions. Salicylic acid acts as a keratolytic agent, softening and promoting the exfoliation of the stratum corneum, which helps to unclog pores and prevent the formation of new comedones. The formulation is typically presented as a lotion that may also contain zinc oxide or titanium dioxide to provide a drying effect and cosmetic coverage of inflamed skin areas.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium bituminosulfonate + salicylic acid.